The compound 3-[(2S)-1-[(3R)-3-(2-Chlorophenyl)-2-(2-Fluorophenyl)pyrazolidin-1-yl]-1 -oxopropan-2-yl]-1-(adamantan-2-yl) urea, referred to as Neurolysin-R2 (NR2), is an allosteric inhibitor of NLN that has been shown to inhibit the proliferation of acute myeloid leukemia (AML) cells in vitro [10,26]. This evidence concerns the gene NLN and acute myeloid leukemia.